Unresectable or Metastatic Left-sided Colorectal Cancer research hub

A randomized, open-label Phase III study of amivantamab and mFOLFOX6 or FOLFIRI versus cetuximab and mFOLFOX6 or FOLFIRI as first-line treatment in participants with KRAS/NRAS and BRAF wild-type unresectable or metastatic left-sided colorectal cancer

This study looks at a new drug called amivantamab for people with advanced bowel cancer on the left side of the colon. Researchers want to see if combining amivantamab with standard chemotherapy works better at slowing down cancer growth than the usual targeted drug, cetuximab, combined with chemotherapy.